Genocea Biosciences

$2.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+1.44%) Today
+$0.04 (+1.89%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell GNCA and other stocks, options, and ETFs commission-free!

About GNCA

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA. The listed name for GNCA is Genocea Biosciences, Inc. Common Stock.

CEO
William D. Clark
Employees
59
Headquarters
Cambridge, Massachusetts
Founded
2006
Market Cap
109.47M
Price-Earnings Ratio
Dividend Yield
Average Volume
247.80K
High Today
$2.19
Low Today
$2.10
Open Price
$2.10
Volume
176.39K
52 Week High
$5.75
52 Week Low
$1.10

Collections

GNCA Earnings

-$0.66
-$0.44
-$0.22
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 11, Pre-Market

You May Also Like